Drugs, gene transfer, signaling factors: A bench to bedside approach to myocardial stem cell therapy

Marton Vertesaljai, Zsolt Piroth, Geza Fontos, Gyorgy Andreka, Gusztav Font, Gergely Szantho, Sandor Lueff, Marienn Reti, T. Masszi, Laszlo Ablonczy, Eszter D. Juhasz, T. Símor, Mark S. Turner, P. Andréka

Research output: Article

10 Citations (Scopus)

Abstract

In the past few years, the dogma that the heart is a terminally differentiated organ has been challenged. Evidence from preclinical investigations emerged that there are cells, even in the heart itself, that may be able to restore impaired cardiac function after myocardial infarction. Although the exact mechanisms by which the infarcted heart can be repaired by stem cells are not yet fully defined, there is a new optimism among cardiologists that this treatment will prove successful in addressing the cause of heart failure after myocardial infarction - myocyte loss. Despite the promising preliminary data of human myocardial stem cell trials, scientists have also focused on the possibility of enhancing the underlying mechanisms of stem cell repair to gain healthier myocardial tissue. Attempts to induce neo-angiogenesis by transfecting stem cells with signaling factors (such as VEGF), to raise the number of endothelial progenitor cells with medical treatments (such as statins), to transfect stem cells with heat shock protein 70 (as a cardioprotective agent against ischemia) and to enhance the healing process after myocardial infarction with the use of various forms of stimulating factors (G-CSF, SCF, GM-CSF) have been made with notable results. In this article, we summarize the evidence from preclinical and clinical myocardial stem cell studies that have addressed the possibility of enhancing the regenerative capacity of cells used after myocardial infarction.

Original languageEnglish
Pages (from-to)227-244
Number of pages18
JournalHeart Failure Reviews
Volume13
Issue number2
DOIs
Publication statusPublished - jún. 2008

Fingerprint

Transfer Factor
Cell- and Tissue-Based Therapy
Stem Cells
Myocardial Infarction
Pharmaceutical Preparations
Genes
Cardiotonic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
HSP70 Heat-Shock Proteins
Granulocyte-Macrophage Colony-Stimulating Factor
Muscle Cells
Vascular Endothelial Growth Factor A
Ischemia
Heart Failure
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Drugs, gene transfer, signaling factors : A bench to bedside approach to myocardial stem cell therapy. / Vertesaljai, Marton; Piroth, Zsolt; Fontos, Geza; Andreka, Gyorgy; Font, Gusztav; Szantho, Gergely; Lueff, Sandor; Reti, Marienn; Masszi, T.; Ablonczy, Laszlo; Juhasz, Eszter D.; Símor, T.; Turner, Mark S.; Andréka, P.

In: Heart Failure Reviews, Vol. 13, No. 2, 06.2008, p. 227-244.

Research output: Article

Vertesaljai, M, Piroth, Z, Fontos, G, Andreka, G, Font, G, Szantho, G, Lueff, S, Reti, M, Masszi, T, Ablonczy, L, Juhasz, ED, Símor, T, Turner, MS & Andréka, P 2008, 'Drugs, gene transfer, signaling factors: A bench to bedside approach to myocardial stem cell therapy', Heart Failure Reviews, vol. 13, no. 2, pp. 227-244. https://doi.org/10.1007/s10741-007-9047-9
Vertesaljai, Marton ; Piroth, Zsolt ; Fontos, Geza ; Andreka, Gyorgy ; Font, Gusztav ; Szantho, Gergely ; Lueff, Sandor ; Reti, Marienn ; Masszi, T. ; Ablonczy, Laszlo ; Juhasz, Eszter D. ; Símor, T. ; Turner, Mark S. ; Andréka, P. / Drugs, gene transfer, signaling factors : A bench to bedside approach to myocardial stem cell therapy. In: Heart Failure Reviews. 2008 ; Vol. 13, No. 2. pp. 227-244.
@article{14f3749c4cee41909346f3414a3b0a51,
title = "Drugs, gene transfer, signaling factors: A bench to bedside approach to myocardial stem cell therapy",
abstract = "In the past few years, the dogma that the heart is a terminally differentiated organ has been challenged. Evidence from preclinical investigations emerged that there are cells, even in the heart itself, that may be able to restore impaired cardiac function after myocardial infarction. Although the exact mechanisms by which the infarcted heart can be repaired by stem cells are not yet fully defined, there is a new optimism among cardiologists that this treatment will prove successful in addressing the cause of heart failure after myocardial infarction - myocyte loss. Despite the promising preliminary data of human myocardial stem cell trials, scientists have also focused on the possibility of enhancing the underlying mechanisms of stem cell repair to gain healthier myocardial tissue. Attempts to induce neo-angiogenesis by transfecting stem cells with signaling factors (such as VEGF), to raise the number of endothelial progenitor cells with medical treatments (such as statins), to transfect stem cells with heat shock protein 70 (as a cardioprotective agent against ischemia) and to enhance the healing process after myocardial infarction with the use of various forms of stimulating factors (G-CSF, SCF, GM-CSF) have been made with notable results. In this article, we summarize the evidence from preclinical and clinical myocardial stem cell studies that have addressed the possibility of enhancing the regenerative capacity of cells used after myocardial infarction.",
keywords = "Cardiac regeneration, Heart failure, Myocardial infarction, Signaling factors, Stem cells, Transplantation",
author = "Marton Vertesaljai and Zsolt Piroth and Geza Fontos and Gyorgy Andreka and Gusztav Font and Gergely Szantho and Sandor Lueff and Marienn Reti and T. Masszi and Laszlo Ablonczy and Juhasz, {Eszter D.} and T. S{\'i}mor and Turner, {Mark S.} and P. Andr{\'e}ka",
year = "2008",
month = "6",
doi = "10.1007/s10741-007-9047-9",
language = "English",
volume = "13",
pages = "227--244",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Drugs, gene transfer, signaling factors

T2 - A bench to bedside approach to myocardial stem cell therapy

AU - Vertesaljai, Marton

AU - Piroth, Zsolt

AU - Fontos, Geza

AU - Andreka, Gyorgy

AU - Font, Gusztav

AU - Szantho, Gergely

AU - Lueff, Sandor

AU - Reti, Marienn

AU - Masszi, T.

AU - Ablonczy, Laszlo

AU - Juhasz, Eszter D.

AU - Símor, T.

AU - Turner, Mark S.

AU - Andréka, P.

PY - 2008/6

Y1 - 2008/6

N2 - In the past few years, the dogma that the heart is a terminally differentiated organ has been challenged. Evidence from preclinical investigations emerged that there are cells, even in the heart itself, that may be able to restore impaired cardiac function after myocardial infarction. Although the exact mechanisms by which the infarcted heart can be repaired by stem cells are not yet fully defined, there is a new optimism among cardiologists that this treatment will prove successful in addressing the cause of heart failure after myocardial infarction - myocyte loss. Despite the promising preliminary data of human myocardial stem cell trials, scientists have also focused on the possibility of enhancing the underlying mechanisms of stem cell repair to gain healthier myocardial tissue. Attempts to induce neo-angiogenesis by transfecting stem cells with signaling factors (such as VEGF), to raise the number of endothelial progenitor cells with medical treatments (such as statins), to transfect stem cells with heat shock protein 70 (as a cardioprotective agent against ischemia) and to enhance the healing process after myocardial infarction with the use of various forms of stimulating factors (G-CSF, SCF, GM-CSF) have been made with notable results. In this article, we summarize the evidence from preclinical and clinical myocardial stem cell studies that have addressed the possibility of enhancing the regenerative capacity of cells used after myocardial infarction.

AB - In the past few years, the dogma that the heart is a terminally differentiated organ has been challenged. Evidence from preclinical investigations emerged that there are cells, even in the heart itself, that may be able to restore impaired cardiac function after myocardial infarction. Although the exact mechanisms by which the infarcted heart can be repaired by stem cells are not yet fully defined, there is a new optimism among cardiologists that this treatment will prove successful in addressing the cause of heart failure after myocardial infarction - myocyte loss. Despite the promising preliminary data of human myocardial stem cell trials, scientists have also focused on the possibility of enhancing the underlying mechanisms of stem cell repair to gain healthier myocardial tissue. Attempts to induce neo-angiogenesis by transfecting stem cells with signaling factors (such as VEGF), to raise the number of endothelial progenitor cells with medical treatments (such as statins), to transfect stem cells with heat shock protein 70 (as a cardioprotective agent against ischemia) and to enhance the healing process after myocardial infarction with the use of various forms of stimulating factors (G-CSF, SCF, GM-CSF) have been made with notable results. In this article, we summarize the evidence from preclinical and clinical myocardial stem cell studies that have addressed the possibility of enhancing the regenerative capacity of cells used after myocardial infarction.

KW - Cardiac regeneration

KW - Heart failure

KW - Myocardial infarction

KW - Signaling factors

KW - Stem cells

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=41249089377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41249089377&partnerID=8YFLogxK

U2 - 10.1007/s10741-007-9047-9

DO - 10.1007/s10741-007-9047-9

M3 - Article

C2 - 17668319

AN - SCOPUS:41249089377

VL - 13

SP - 227

EP - 244

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 2

ER -